Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Fidelity Brokerage Services LLC submitted a Form 144 notice listing proposed sales of common stock on 05/29/2026. The filing lists multiple tranches tied to option grants with quantities of 2,250, 9,138, 11,682, and 22,870 shares shown as to be sold on that date.
The entries reference option grant dates (09/05/2019; 02/25/2020; 02/23/2021; 09/09/2020) and indicate cash as the transaction type. The filing names Fidelity Brokerage Services LLC and lists the exchange as NYSE.
Thermo Fisher Scientific Inc. reported the results of shareholder voting from its May 20, 2026 annual meeting. All nominated directors were elected, each receiving substantially more votes "For" than "Against." For example, Debora L. Spar received 314,426,121 votes for and 311,821 against.
A key outcome was that a non-binding, advisory proposal on the compensation of the company’s named executive officers was not approved, with 99,928,178 votes for and 214,525,673 against. Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, by 296,866,709 votes for and 36,064,900 against.
Thermo Fisher Scientific director Dion J. Weisler received a grant of 499 shares of Common Stock, increasing his direct holdings. On the same date, 80.287 shares were withheld at $451.79 per share to satisfy tax obligations related to this award, leaving him with 4,947.384 directly held shares.
Thermo Fisher Scientific director Scott M. Sperling received an award of 499 shares of Common Stock at no cost, classified as a grant or other acquisition. After this compensation grant, he directly holds 69,479 shares of Thermo Fisher Scientific common stock.
Spar Debora L reported acquisition or exercise transactions in this Form 4 filing.
THERMO FISHER SCIENTIFIC INC. director Debora L. Spar reported receiving a grant of 499 shares of Common Stock on May 20, 2026. The award carried a stated price of $0.00 per share, indicating compensation rather than an open-market purchase. After this grant, she directly holds 2,610 shares of Thermo Fisher stock, reflecting a routine equity compensation transaction rather than a market trade.
Lynch Karen S reported acquisition or exercise transactions in this Form 4 filing.
THERMO FISHER SCIENTIFIC INC. director Karen S. Lynch reported a stock award of 499 shares of common stock on May 20, 2026, recorded at $0.0000 per share. After this grant, she directly owns 1,159 common shares. The filing also reports 76 additional common shares held indirectly through a living trust.
Keith R. Alexandra reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Keith R. Alexandra received a stock grant of 499 shares of Common Stock as compensation, not an open-market purchase. The shares were awarded at a stated price of $0.00 per share, increasing his directly held position to 2,602 shares following the transaction.
JOHNSON JENNIFER M reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Jennifer M. Johnson reported receiving a grant of 499 shares of Common Stock on May 20, 2026. The award was recorded at a price of $0.00 per share, indicating it was part of her director compensation rather than an open-market purchase. After this grant, she directly holds a total of 1,403 shares of Thermo Fisher Scientific common stock.
Jacks Tyler reported acquisition or exercise transactions in this Form 4 filing.
THERMO FISHER SCIENTIFIC INC. director Tyler Jacks received a grant of 499 shares of common stock on May 20, 2026. The award was granted at no cash cost per share and increased his directly held position to 9,462 shares. This is a routine compensation-related equity grant rather than an open-market purchase.